Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients-Reference-Cited by-同舟云学术

Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients

Published:2016-09 Issue:3 Volume:15 Page:257-263
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Sun Julia,Ilich Alastair I.,Kim Christina A.,Chu Michael P.,Wong Grace G.,Ghosh Sunita,Danilak Melanie,Mulder Karen E.,Spratlin Jennifer L.,Chambers Carole R.,Sawyer Michael B.

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference28 articles.

1. Clinical pharmacokinetics of capecitabine;Reigner;Clin Pharmacokinet,2001

2. Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review;Koukourakis;Molecules,2008

3. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer;Borner;Eur J Cancer,2002

4. Patient preferences for oral versus intravenous palliative chemotherapy;Liu;J Clin Oncol,1997

5. Capecitabine (xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma;Twelves;Eur J Cancer,2001

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential functionality of fluoropyrimidine nucleosides for safe cancer therapy;Anti-Cancer Drugs;2024-08-20

2. Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer;Biomarker Insights;2024-01

3. Influence of proton pump inhibitors on the pathological response of rectal cancer: a multicentre study;ecancermedicalscience;2023-08-10

4. Thésaurus d’interventions pharmaceutiques associées aux prescriptions injustifiées d’inhibiteurs de la pompe à protons;Annales Pharmaceutiques Françaises;2023-05

5. Challenges in Diagnosis and Treatment of Pancreatic Exocrine Insufficiency among Patients with Pancreatic Ductal Adenocarcinoma;Cancers;2023-02-20